3 completed, 1 terminated. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 1 | Terminated 1 |
Follow MM-111: new trials by email Literature Review of MM-111 trials Research Report on MM-111
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach MM-111, Paclitaxel, Trastuzumab - HER-2 Gene Amplification, Esophagus Cancer | Phase 2 | Terminated | Merrimack Pharmaceuticals | 84 | 2013-01-01 | 2017-06-22 |
| A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer Cisplatin, Capecitabine, Trastuzumab and MM-111, Lapatinib +/- Trastuzumab and MM-111, Paclitaxel, Trastuzumab and MM-111 - HER-2 Gene Amplification | Phase 1 | Completed | Merrimack Pharmaceuticals | 100 | 2011-01-01 | 2015-12-16 |
| MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer MM-111 + Herceptin - Breast Neoplasms | Phase 1 | Completed | Merrimack Pharmaceuticals | 16 | 2010-04-01 | 2015-01-07 |
| A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers MM-111 - Her2 Amplified Solid Tumors, Metastatic Breast Cancer | Phase 1 | Completed | Merrimack Pharmaceuticals | 20 | 2009-06-01 | 2015-01-13 |
Breast Neoplasms (2) · Esophageal Neoplasms (1) · Neoplasm Metastasis (1) · Stomach Neoplasms (1)
United States (4)
Akos Czibere, MD, PhD (1) · Michaela Higgins, MD (1) · Muralidhar Beeram, MD (1)